Catalogue


Glutamate-related biomarkers in drug development for disorders of the nervous system [electronic resource] : workshop summary /
Diana E. Pankevich, Miriam Davis, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
imprint
Washington, D.C. : National Academies Press, c2011.
description
xii, 61 p. : ill. (some col.) ; 23 cm.
ISBN
0309212219, 9780309212212
format(s)
Book
Holdings
More Details
imprint
Washington, D.C. : National Academies Press, c2011.
isbn
0309212219
9780309212212
restrictions
Licensed for access by U. of T. users.
abstract
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. This book investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.
catalogue key
9065265
 
Includes bibliographical references (p. 39-43)
A Look Inside
Summaries
Description for Bookstore
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.
Description for Bookstore
Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The IOM's Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers.
Table of Contents
Introductionp. 1
Glutamate Biomarkersp. 2
Workshop Goalsp. 3
Overview of the Glutamatergic Systemp. 5
Glutamate Receptorsp. 7
Glutamate Transportersp. 9
Glutamate Biomarkersp. 11
Biomarkers of Engagement and Efficacyp. 12
Physiological Biomarkersp. 13
Cognitive Biomarkersp. 20
Imaging Biomarkersp. 22
Treatment Implications of Biomarkersp. 27
Target Developmentsp. 27
Patient Stratificationp. 28
Side-Effect Reductionp. 30
Challenges and Opportunitiesp. 33
Challengesp. 34
Opportunitiesp. 34
Summaryp. 37
Appendixes
Referencesp. 39
Registered Attendeesp. 45
Agendap. 49
Table of Contents provided by Ingram. All Rights Reserved.

This information is provided by a service that aggregates data from review sources and other sources that are often consulted by libraries, and readers. The University does not edit this information and merely includes it as a convenience for users. It does not warrant that reviews are accurate. As with any review users should approach reviews critically and where deemed necessary should consult multiple review sources. Any concerns or questions about particular reviews should be directed to the reviewer and/or publisher.

  link to old catalogue

Report a problem